Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulias V, Mavroudis D. Saloustros E, et al. Among authors: christophyllakis c. Breast Cancer Res Treat. 2014 Dec;148(3):591-7. doi: 10.1007/s10549-014-3202-5. Epub 2014 Nov 16. Breast Cancer Res Treat. 2014. PMID: 25399229 Clinical Trial.
A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.
Pallis AG, Agelidou A, Agelaki S, Varthalitis I, Pavlakou G, Gerogianni A, Papakotoulas P, Rapti A, Chandrinos V, Christophyllakis C, Georgoulias V. Pallis AG, et al. Among authors: christophyllakis c. Lung Cancer. 2009 Aug;65(2):187-91. doi: 10.1016/j.lungcan.2008.11.002. Epub 2008 Dec 18. Lung Cancer. 2009. PMID: 19100647 Clinical Trial.
Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.
Vetsika EK, Papadimitraki E, Aggouraki D, Konsolakis G, Mela ME, Kotsakis A, Christou S, Patramani S, Alefantinou M, Kaskara A, Christophyllakis C, Kosmatopoulos K, Georgoulias V, Mavroudis D. Vetsika EK, et al. Among authors: christophyllakis c. J Immunother. 2011 Nov-Dec;34(9):641-50. doi: 10.1097/CJI.0b013e31823284a6. J Immunother. 2011. PMID: 21989412
Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.
Karampeazis A, Vamvakas L, Kotsakis A, Christophyllakis C, Kentepozidis N, Chandrinos V, Agelidou A, Polyzos A, Tsiafaki X, Hatzidaki D, Georgoulias V. Karampeazis A, et al. Among authors: christophyllakis c. J Geriatr Oncol. 2017 Jan;8(1):23-30. doi: 10.1016/j.jgo.2016.05.002. Epub 2016 Jun 2. J Geriatr Oncol. 2017. PMID: 27264267
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D. Kontopodis E, et al. Among authors: christophyllakis ch. Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60. doi: 10.1007/s00280-014-2628-0. Epub 2014 Nov 15. Cancer Chemother Pharmacol. 2015. PMID: 25398698 Clinical Trial.
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.
Tryfonidis K, Boukovinas I, Xenidis N, Christophyllakis C, Papakotoulas P, Politaki E, Malamos N, Polyzos A, Kakolyris S, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group. Tryfonidis K, et al. Among authors: christophyllakis c. Breast. 2013 Dec;22(6):1171-7. doi: 10.1016/j.breast.2013.08.017. Epub 2013 Oct 1. Breast. 2013. PMID: 24091128 Free article. Clinical Trial.
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L, Georgoulias V, Polyzos A. Souglakos J, et al. Among authors: christophyllakis ch. Br J Cancer. 2012 Jan 31;106(3):453-9. doi: 10.1038/bjc.2011.594. Epub 2012 Jan 12. Br J Cancer. 2012. PMID: 22240792 Free PMC article. Clinical Trial.
Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.
Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulias V, Christophyllakis Ch, Cordopatis P, Kosmatopoulos K, Mavroudis D. Kotsakis A, et al. Among authors: christophyllakis ch. Ann Oncol. 2012 Feb;23(2):442-9. doi: 10.1093/annonc/mdr396. Epub 2011 Aug 25. Ann Oncol. 2012. PMID: 21873272 Free article. Clinical Trial.
Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.
Karampeazis A, Vamvakas L, Agelidou A, Kentepozidis N, Chainis K, Chandrinos V, Vardakis N, Pallis AG, Christophyllakis C, Georgoulias V. Karampeazis A, et al. Among authors: christophyllakis c. Clin Lung Cancer. 2011 May;12(3):155-60. doi: 10.1016/j.cllc.2011.03.015. Epub 2011 Apr 27. Clin Lung Cancer. 2011. PMID: 21663857 Clinical Trial.
15 results